N6-methyladenosine reader YTHDF3-mediated zinc finger protein 41 inhibits hepatocellular carcinoma progression by transcriptional repression of Snail

Abstract

Advanced metastasis of hepatocellular carcinoma (HCC) significantly contributes to high death rates among patients. The efficiency of targeted therapies and chemotherapeutic agents shows individual variability. Therefore, there is no effective treatment for advanced HCC. Zinc finger proteins (ZFPs) are known to be crucial in various tumors, especially on HCC. In our study, we verified that ZFP41 could suppress the progression and metastasis of HCC through in vitro and in vivo experiments. During the past years, N6-methyladenine (m⁶A) regulation has also been increasingly reported in HCC. To investigate whether ZFP41 could be regulated via m⁶A methylation, our results showed that YTHDF3 bound to the mRNA of ZFP41 and degrade it. Subsequently, to further elucidate the function of ZFP41, we identified Snail, a well-known oncogenic molecule, through RNA-seq. As a canonical component in the epithelial-to-mesenchymal transition (EMT) pathway, Snail plays a pivotal role and is a critical marker for tumor invasion and metastasis. Our results showed ZFP41 could inhibit Snail and the EMT pathway through its transcriptional repression. In conclusion, our study revealed that ZFP41 is a potential prognostic element for patients with HCC, and targeting ZFP41 might be used for translational clinical applications as a promising therapeutic target.

Keywords

EMT / hepatocellular carcinoma / m6A / transcription regulation / ZFP41

References

[1] Merle P, Kudo M, Edeline J, et al. Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: longer term follow-up from the phase 3 KEYNOTE-240 trial. Liver Cancer. 2023; 12(4): 309-320.

[2] Foerster F, Gairing SJ, Muller L, Galle PR. NAFLD-driven HCC: safety and efficacy of current and emerging treatment options. J Hepatol. 2022; 76(2): 446-457.

[3] Kim S, Shendure J. Mechanisms of interplay between transcription factors and the 3D genome. Mol Cell. 2019; 76(2): 306-319.

[4] Chen A, Koehler AN. Transcription factor inhibition: lessons learned and emerging targets. Trends Mol Med. 2020; 26(5): 508-518.

[5] Zhang L, Huo Q, Ge C, et al. ZNF143-mediated H3K9 trimethylation upregulates CDC6 by activating MDIG in hepatocellular carcinoma. Cancer Res. 2020; 80(12): 2599-2611.

[6] Wang F, Hu Y, Wang H, et al. LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2. J Exp Clin Cancer Res. 2023; 42(1): 267.

[7] Zhou Y, Yan J, Huang H, et al. The m(6)A reader IGF2BP2 regulates glycolytic metabolism and mediates histone lactylation to enhance hepatic stellate cell activation and liver fibrosis. Cell Death Dis. 2024; 15(3): 189.

[8] Wang Z, Shang J, Qiu Y, et al. Suppression of the METTL3-m(6)A-integrin beta1 axis by extracellular acidification impairs T cell infiltration and antitumor activity. Cell Rep. 2024; 43(2): 113796.

[9] Yan Y, Luo A, Liu S, et al. METTL3-mediated LINC00475 alternative splicing promotes glioma progression by inducing mitochondrial fission. Research. 2024(7):0324.

[10] Zhou R, Ni W, Qin C, et al. A functional loop between YTH domain family protein YTHDF3 mediated m(6)A modification and phosphofructokinase PFKL in glycolysis of hepatocellular carcinoma. J Exp Clin Cancer Res. 2022; 41(1): 334.

[11] Liu T, Zheng X, Wang C, et al. The m(6)A “reader” YTHDF1 promotes osteogenesis of bone marrow mesenchymal stem cells through translational control of ZNF839. Cell Death Dis. 2021; 12(11): 1078.

[12] Chen Y, Ling Z, Cai X, et al. Activation of YAP1 by N6-methyladenosine-modified circCPSF6 drives malignancy in hepatocellular carcinoma. Cancer Res. 2022; 82(4): 599-614.

[13] Saitoh M. Transcriptional regulation of EMT transcription factors in cancer. Semin Cancer Biol. 2023; 97: 21-29.

[14] Gu X, Li P, Gao X, et al. RNA 5-methylcytosine writer NSUN5 promotes hepatocellular carcinoma cell proliferation via a ZBED3-dependent mechanism. Oncogene. 2024; 43(9): 624-635.

[15] Kan A, Liu S, He M, et al. MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma. JHEP Reports. 2024; 6(1): 100939.

[16] Guo HJ, Wang LJ, Wang C, et al. Identification of an Apis cerana zinc finger protein 41 gene and its involvement in the oxidative stress response. Arch Insect Biochem Physiol. 2021; 108(1): e21830.

[17] Li K, Chen J, Zhang C, et al. The CTBP2-PCIF1 complex regulates m6Am modification of mRNA in head and neck squamous cell carcinoma. J Clin Invest. 2023; 133(20): e170173.

[18] Zhou KI, Shi H, Lyu R, et al. Regulation of co-transcriptional pre-mRNA splicing by m(6)A through the low-complexity protein hnRNPG. Mol Cell. 2019; 76(1): 70-81.

[19] Imbeault M, Helleboid PY, Trono D. KRAB zinc-finger proteins contribute to the evolution of gene regulatory networks. Nature. 2017; 543(7646): 550-554.

[20] Jeong DW, Park JW, Kim KS, et al. Palmitoylation-driven PHF2 ubiquitination remodels lipid metabolism through the SREBP1c axis in hepatocellular carcinoma. Nat Commun. 2023; 14(1): 6370.

[21] Tan S, Wang Z, Li N, et al. Transcription factor Zhx2 is a checkpoint that programs macrophage polarization and antitumor response. Cell Death Differ. 2023; 30(9): 2104-2119.

[22] Zhao Q, Zhang C, Zhang X, et al. ZNF281 inhibits mitochondrial biogenesis to facilitate metastasis of hepatocellular carcinoma. Cell Death Discov. 2023; 9(1): 396.

[23] Shen S, Jin H, Zhang X, et al. LINC00426, a novel m(6)A-regulated long non-coding RNA, induces EMT in cervical cancer by binding to ZEB1. Cell Signal. 2023; 109: 110788.

[24] Li N, Kang Y, Wang L, et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci USA. 2020; 117(33): 20159-20170.

[25] Hu X, Wu J, Feng Y, et al. METTL3-stabilized super enhancers-lncRNA SUCLG2-AS1 mediates the formation of a long-range chromatin loop between enhancers and promoters of SOX2 in metastasis and radiosensitivity of nasopharyngeal carcinoma. Clin Transl Med. 2023; 13(9): e1361.

[26] Zhuang A, Gu X, Ge T, et al. Targeting histone deacetylase suppresses tumor growth through eliciting METTL14-modified m(6) A RNA methylation in ocular melanoma. Cancer Commun (Lond). 2023; 43(11): 1185-1206.

[27] Ye M, Chen J, Yu P, et al. WTAP activates MAPK signaling through m6A methylation in VEGFA mRNA-mediated by YTHDC1 to promote colorectal cancer development. FASEB J. 2023; 37(8): e23090.

[28] Liu Y, Song R, Zhao L, et al. A demethylase ALKBH5 is required for antibacterial innate defense by intrinsic motivation of neutrophil migration. Signal Transduct Target Ther. 2022; 7(1): 194.

[29] Hu B, Gao J, Shi J, Wen P, Guo W, Zhang S. A reader YTHDF3 triggers the progression of hepatocellular carcinoma through the YTHDF3/m(6) A-EGFR/STAT3 axis and EMT. Mol Carcinog. 2023; 62(10): 1599-1614.

[30] Qiu X, Yang S, Wang S, et al. M(6)A demethylase ALKBH5 regulates PD-L1 expression and tumor immunoenvironment in intrahepatic cholangiocarcinoma. Cancer Res. 2021; 81(18): 4778-4793.

[31] Xiong J, He J, Zhu J, et al. Lactylation-driven METTL3-mediated RNA m(6)A modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol Cell. 2022; 82(9): 1660-1677.

[32] Song H, Song J, Cheng M, et al. METTL3-mediated m(6)A RNA methylation promotes the anti-tumour immunity of natural killer cells. Nat Commun. 2021; 12(1): 5522.

[33] Wang W, Shao F, Yang X, et al. METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N(6)-methyladenosine-dependent YTHDF binding. Nat Commun. 2021; 12(1): 3803.

[34] Wang Q, Chen C, Ding Q, et al. METTL3-mediated m(6)A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2020; 69(7): 1193-1205.

[35] Wang C, Dou C, Wang Y, Liu Z, Roberts L, Zheng X. TLX3 repressed SNAI1-induced epithelial-mesenchymal transition by directly constraining STAT3 phosphorylation and functionally sensitized 5-FU chemotherapy in hepatocellular carcinoma. Int J Biol Sci. 2019; 15(8): 1696-1711.

[36] Kielbik M, Przygodzka P, Szulc-Kielbik I, Klink M. Snail transcription factors as key regulators of chemoresistance, stemness and metastasis of ovarian cancer cells. Biochim Biophys Acta Rev Cancer. 2023; 1878(6): 189003.

[37] Ungefroren H, Konukiewitz B, Braun R, Wellner UF, Lehnert H, Marquardt JU. TAp73 inhibits EMT and cell migration in pancreatic cancer cells through promoting SMAD4 expression and SMAD4-dependent inhibition of ERK activation. Cancers (Basel). 2023; 15(15): 3791.

[38] Yang S, Liu Y, Tang C, et al. The CPT1A/Snail axis promotes pancreatic adenocarcinoma progression and metastasis by activating the glycolytic pathway. iScience. 2023; 26(10): 107869.

[39] Zou X, Ma L, Zhang Y, et al. GATA zinc finger protein p66beta promotes breast cancer cell migration by acting as a co-activator of Snail. Cell Death Dis. 2023; 14(6): 382.

[40] Zhu W, Ye B, Yang S, Li Y. USP10 promotes intrahepatic cholangiocarcinoma cell survival and stemness via SNAI1 deubiquitination. J Mol Histol. 2023; 54(6): 703-714.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.